Navigation Links
QIAGEN N.V. (Nasdaq: QGEN) Invites You to Join Its Third Quarter 2007 Earnings Conference Call on the Web
Date:10/30/2007

VENLO, The Netherlands, Oct. 30 /PRNewswire-FirstCall/ -- In conjunction with QIAGEN's Third Quarter 2007 Earnings release, you are invited to listen to its conference call which will be broadcast live over the Internet on Tuesday, November 6, 2007 at 9:30 a.m. EST, with Peer M. Schatz, President and Chief Executive Officer and Roland Sackers, Chief Financial Officer.

What: QIAGEN N.V. -- Third Quarter 2007 Earnings Announcement

When: Tuesday, November 6, 2007 at 9:30 a.m. EST

Where: http://www.QIAGEN.com/goto/061107

How: Live over the Internet -- Simply log on to the Web at the

address above.

The corresponding presentation slides are available to download

in the investor relations section of QIAGEN's website at:

http://www.QIAGEN.com/goto/061107

Contact: Andreas Marathovouniotis, Russo Partners, 212-845-4253

QIAGEN N.V., a Netherlands holding company, is a leading provider of innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions. QIAGEN has developed a comprehensive portfolio of more than 500 proprietary, consumable products and automated solutions for sample collection, and nucleic acid and protein handling, separation, and purification. QIAGEN also supplies diagnostic kits, tests, and assays for human and veterinary molecular diagnostics. The company's products are sold to academic research markets, and to leading pharmaceutical and biotechnology companies; as well as to diagnostics laboratories. QIAGEN also provides purification and testing solutions to applied testing markets: such as forensics, animal or food testing, and pharmaceutical process control.

QIAGEN employs more than 2,600 people worldwide. QIAGEN products are sold through a dedicated sale
'/>"/>

SOURCE QIAGEN N.V.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
2. Neurologix to Present at the Third Annual C.E. Unterberg Towbin Emerging Growth Conference
3. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
4. Can-Fite Proceeds with Development of Third Drug; Progress in Development of CF502 Will Be Presented at the Annual European Congress of Rheumatology
5. One-Third of Patients Discontinue Common Breast Cancer Therapy
6. CeNeRx BioPharma Announces Positive Phase I Results in First Human Trial of Third Generation RIMA Antidepressant
7. Phosphagenics to Commence Phase 1b Transdermal Insulin Clinical Trial in Second Quarter
8. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
9. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
11. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/686gwf/investigation ... Report on China,s Bevacizumab Market ,2010-2019" report to ... trade name of Avastin, bevacizumab injection is the first ... was approved by CFDA to treat metastatic colorectal cancer. ... all come from Roche and its subsidiary Genectech. ...
(Date:8/28/2015)... 2015 Research and ... of the "Investigation Report on China,s Quetiapine ... Developed by AstraZeneca plc, quetiapine (under the ... for the treatment of schizophrenia. Approved by CFDA ... in the Catalogue of Drugs for the Basic ...
(Date:8/28/2015)... Aug. 28, 2015  IP Shakti, LLC, today announced that ... Logo - http://photos.prnewswire.com/prnh/20150827/261551LOGO ... "Our new corporate identity signifies our transformation into a company ... analytics platform for patent claim validity." ... the proprietary AIA Shield™ platform, the Company commenced a corporate ...
Breaking Medicine Technology:Investigation Report on China's Bevacizumab Market 2015-2019 2China Quetiapine Market Investigation Report 2010-2019 2IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2
... Tenn., Aug. 30 ,Palatin Technologies, Inc. (Amex: ... ) announced today that they have delayed plans ... bremelanotide, a first in class,melanocortin agonist drug candidate, ... decision follows responses from representatives of,the U.S. Food ...
... FRANCISCO, Calif., Aug. 29 ,Exelixis, Inc. (Nasdaq: EXEL ... for analysts and investors in conjunction with the International,Association ... Conference on,Lung Cancer. The webcast will be held on ... During the webcast, Exelixis management will,discuss data from a ...
Cached Medicine Technology:King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction 2Exelixis Announces September 5 Webcast of Its 2007 IASLC Investor and Analyst Briefing 2
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... For Dallas, ... is taking part with their subsidiary USPI Tenet Health. , The American Heart Association ... heart disease and stroke. They believe that together, a difference can be made. Walkers ...
(Date:8/28/2015)... ... ... The 6th Annual Survivor in the City, Chicago silent auction and cocktail ... its cadre of widespread support—an official letter of support and gratitude from the Mayor ... and the University of Illinois at Chicago’s Department of Neurosurgery, the Brain Aneurysm Foundation ...
(Date:8/28/2015)... ... ... Saint Petersburg, FL —Pocket Protein™, a protein beverage that ... lactose or caffeine in a convenient 2 oz. pouch that never needs refrigeration, ... , Five consumer packaged goods (CPG) products were selected by the SupplySide editorial ...
(Date:8/28/2015)... Boynton Beach, FL. (PRWEB) , ... August 28, ... ... creating problems for businesses nationwide. Addictions specialist, Dr. James Strawbridge, gives a new ... Strawbridge believes that it should begin with the employer and employees getting together ...
(Date:8/28/2015)... ... 28, 2015 , ... CARF International announced that West Ridge ... treatment and intensive family based services. , By pursuing and achieving accreditation, West ... of excellence. As a nonprofit charity for more than 50 years, West Ridge ...
Breaking Medicine News(10 mins):Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 3Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3Health News:West Ridge Academy Awarded CARF Three-Year Accrediation 2
... Cellular damage induced by oxygen free radicals may be ... new study. //This groundbreaking study conducted by neuroscientists at ... of complex I, a protein that plays a major ... has been blamed for cellular damage in Parkinson’s disease. ...
... yet ascertained the top floors of the Melbourne office block ... the cause of illnesses.// ,Tests on radiofrequency emissions, ... any link as yet to the seven cases of brain ... of these seven cases were employees who had worked on ...
... genetic disorder which completely affects the immune system. In ... //therapy was successfully used to cure this life threatening ... Of Veterinary Medicine and the National Institute of Allergy ... as a vector for the correct gene of XSCID. ...
... of several previous studies of TNF- (tumor necrosis factor) ... that use of these drugs causes an increased risk ... study shows a strong association between treatment with TNF-blocking ... pneumonia, and cancers,' says Eric Matteson, M.D., Mayo Clinic ...
... a pigment that imparts tomatoes its characteristic red color ... ideal for prevention of strokes and heart attacks.// Previous ... chemical. ,According to scientists, the stickiness of ... - was reduced by 70 percent when 220 volunteers ...
... issue of Cancer Cell says that scientists have identified ... how cancer progresses.// This molecule was found to inhibit ... vivo as well as in vitro. , ,This ... inhibitors must display a broad reactivity to effectively attenuate ...
Cached Medicine News:Health News:Oxygen-Induced Damage A Leading Cause For Parkinson’s Diseas 2Health News:In-Vivo Gene Therapy Technique to Cure XSCID in Basset Pups 2Health News:In-Vivo Gene Therapy Technique to Cure XSCID in Basset Pups 3Health News:Risk of Cancer from Drugs for Rheumatoid Arthritis 2Health News:Risk of Cancer from Drugs for Rheumatoid Arthritis 3Health News:Discovery Of New Molecule Could Solve Cancer Spread Mystery 2
... point-of-care device for the qualitative detection of drug ... TOX/See device can detect up to nine of ... 8 minutes and requires only a few drops ... to maximize convenience and ease of use. TOX/See ...
... point-of-care device for the qualitative detection of drug ... TOX/See device can detect up to nine of ... 8 minutes and requires only a few drops ... to maximize convenience and ease of use. TOX/See ...
... hand-held, point-of-care device for the qualitative detection of ... The TOX/See device can detect up to nine ... to 8 minutes and requires only a few ... packaged to maximize convenience and ease of use. ...
... is a 1-step, hand-held, point-of-care device for the ... human urine. The TOX/See device can detect ... drugs in 3 to 8 minutes and requires ... cassette is individually packaged to maximize convenience and ...
Medicine Products: